Profectus BioSciences is an innovative clinical stage vaccine company devoted to preventing and treating viral diseases and malaria through the application of its proprietary pDNA and rVSV platform.

February, 2013: Althea Technologies & Profectus Biosciences sign manufacturing agreement for plasmid DNA production. Learn More >

December, 2012: Profectus BioSciences, Inc. Vesicular Stomatitis Virus‐Vectored HIV‐1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial. Learn More >

August 14, 2012: Profectus BioSciences, Inc. Announces Initiation of Clinical Trial Evaluating pDNA Prime/rVSV Boost Regimen to Prevent HIV Infection. Learn More >

May 9, 2012: Profectus BioSciences, Inc. Receives $5.6M grant to develop a vaccine to protect humans against infection with Nipah/Hendra viruses. Learn More >

May 2, 2012: Profectus BioSciences, Inc. Receives NIAID Grant to Develop a Vesicular Stomatitis Virus. Learn More >